Data investigation

Tirzepatide in Ten- to Seventeen-Year-Olds

Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Youth-onset type 2 diabetes is not adult diabetes in a smaller body. It moves faster, responds worse to the medicines that work in adults, and has very few approved treatments. In a trial of 99 people aged 10 to 17, tirzepatide lowered HbA1c by 2.23%, while the placebo group’s blood sugar went up.[1]

Why the placebo column matters most

In most diabetes trials the control group holds roughly steady. Here it deteriorated. An HbA1c rise of 0.05% over 30 weeks is small in absolute terms, but it is in the wrong direction, in children whose diabetes was already inadequately controlled on metformin, basal insulin, or both. That is what an aggressive disease looks like in a control group.

In the placebo group, HbA1c rose 0.05% over 30 weeks.

That deterioration is also part of why the treatment effect here is so large. The estimated difference between groups was 2.28 percentage points (95% CI −2.87 to −1.69). Some of that gap is the drug working, and some is the comparison arm losing ground.

What was measured

Across 39 sites in eight countries, participants aged 10 to under 18 with youth-onset type 2 diabetes were randomized in equal thirds to tirzepatide 5 mg, tirzepatide 10 mg, or placebo, for 30 weeks double-blind. Everyone then received tirzepatide for a further 22 weeks. Average age was 14.7, average starting HbA1c 8.04%, and 61% were girls.

SURPASS-PEDS at 30 weeks.[1]
OutcomeTirzepatidePlacebo
HbA1c change (pooled doses)−2.23%+0.05%
BMI change, 5 mg−7.4%−0.4%
BMI change, 10 mg−11.2%−0.4%
Stopped for an adverse event2 of 32 (6%) on 5 mg—

Gastrointestinal effects were the most common adverse events. All were mild to moderate, and they became less frequent over time. No deaths occurred. The authors describe the safety profile as consistent with what has been seen in adults.

What 99 children cannot tell you

Thirty-two, thirty-three and thirty-four participants per arm. A trial that size can detect a large effect on blood sugar, and it cannot characterize an uncommon harm. In a ten-year-old, a harm missed here has sixty years to play out. That does not argue against the drug, but it does mean the size of this evidence base should be stated whenever its results are.

The 52-week durability claim needs the same care. The double-blind comparison ran 30 weeks; after that everyone received tirzepatide. So “sustained to 52 weeks” describes people continuing to do well on a drug, with no control group left to compare them against.

  • Growth and puberty are not addressed by 30 weeks of data.
  • Bone accrual, which happens largely in adolescence, is not measured.
  • What happens on stopping is unstudied in this age group, and nobody plans to medicate a ten-year-old indefinitely without knowing.
  • The trial was funded by Eli Lilly, which makes tirzepatide.

Where this sits among the pediatric evidence

Three separate questions get conflated in coverage of these drugs in young people, and they have different evidence behind them.

Three different pediatric questions.
QuestionWhere we cover it
Weight in adolescents with obesityGLP-1 drugs in teenagers
Metabolic markers in those same adolescentswhat changed in the teenagers’ bloodwork
Blood sugar in youth-onset type 2 diabetesThis page

The distinction matters because the third has something the first two do not: a direct measure of a condition that is actively damaging the child while the trial runs. In diabetes, HbA1c measures the disease itself; it is also the standard surrogate for complications that take decades to appear. That makes this the strongest pediatric case in the class, though it is still 99 children over 30 weeks.

Frequently Asked Questions

In this trial, pooled tirzepatide lowered HbA1c by 2.23% over 30 weeks while the placebo group rose by 0.05%, in 99 participants aged 10 to 17. BMI fell 7.4% on 5 mg and 11.2% on 10 mg against 0.4% on placebo.
Youth-onset type 2 diabetes progresses faster and responds less well to existing treatments than adult-onset disease. A control group losing ground over 30 weeks is what that looks like.
The effect on blood sugar is large and clear. The trial is small, with around 33 participants per arm. That is enough to detect a large benefit and not enough to characterize uncommon harms.
Participants continued to do well through 52 weeks, but the double-blind comparison ended at 30 weeks and everyone received tirzepatide afterward. There was no control group left for the second half.
Effects on growth, puberty and bone accrual, what happens on stopping, and anything beyond a year. None of those is addressed by 30 weeks of double-blind data in 99 children.

References

  1. 1.Hannon TS, Chao LC, Barrientos-Pérez M, et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet. 2025. PMID: 40975112.

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.1

Direct Meds

8.2

bmiMD

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →